CASP3 and plasma cell leukemia: This is in agreement with results published by Esparis-Ogando et al. showing that treatment with bortezomib in plasma cell leukemia leads to PARP cleavage and upregulation of caspase 3, which are responsible for apoptosis in this specific cellular context [36].